Discover Great Companies Discover Great Clients
Popularity  3.9万   |   Followers  23   |   Likes  25   |   Feedback  8 Claim this company

A clinical-stage global biopharmaceutical company

No.288 Yuhang District Popularity Ranking Hangzhou Zhejiang No.5 Biopharmaceuticals Technology No.6 Biotechnology Healthcare No.7 Antigens No.8 Genetic Engineering No.11 Zhong Liu Yao Products No.18 Peptides No.18 Antibodies No.20 Innovative Drugs No.22 APIs No.28 Pharmaceutical R&D No.31 Biotechnology Pharmaceuticals No.35 Sheng Ming Ke Xue 院士工作站 省级高新技术企业 国家高新技术企业 高新技术企业 科技型中小企业 省科技型中小企业
More

Company Overview

  • Nature: Private Enterprise Size: 100-499 employees Founded: 22年
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: Hangzhou Adlai Nortye Biopharma Co., Ltd.。

Development Stage

  • Stage: IPO上市, 。
  • Ranking: Ranked #5 in Hangzhou Biopharmaceuticals Technology Company by popularity Ranked #6 in Hangzhou Biotechnology Healthcare Company by popularity Ranked #7 in Hangzhou Antigens Company by popularity Ranked #8 in Hangzhou Genetic Engineering Company by popularity
  • Honors: 院士工作站 省级高新技术企业 According to algorithm
  • News: 2021-12-30:阿诺医药宣布与宝太生物达成多款化合物的技术及商业合作。
  • Salary: 64.3% of positions earn 10-30K,。Master's salary: ¥23.8K, Doctorate salary: ¥29.3K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 42.9%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 35.7%, "Scientific Research": 28.6%。
  • Recruiting: In 2026 vs 2025grew by 367%. Demand for highly educated talent: Master's: 14, Doctorate: 4.
  • Requirement: Education: 硕士 leads with 42.9%. Experience: 不限 leads with 47.6%.
  • Region: Distributed across 1 regions, 杭州: 76.2%, 上海: 11.9%, 北京: 4.8%, 武汉: 4.8%.

About the Company

[Summary] A clinical-stage global biopharmaceutical company

About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a clinical-stage global biopharmaceutical company focused on the research and development of "global new" oncology drugs, with R&D and clinical operations centers in both China and the United States. The company has assembled experienced leadership and R&D teams, established a differentiated oncology product pipeline, and collaborates with several renowned leading pharmaceutical companies to accelerate drug discovery and development. We are committed to becoming an innovative R&D enterprise dedicated to creating "global new" oncology drugs, benefiting patients in China and worldwide with better treatment options.

Leveraging our dual-center R&D layout in China and the United States, we have built an influential pipeline focused on two core areas: ① Targeted therapeutic strategies for RAS-driven tumors: including AN9025 (an oral pan-RAS(ON) inhibitor), and AN4035 (a novel ADC targeting CEACAM5 that precisely delivers a potent pan-RAS(ON) inhibitor to tumors); ② Next-generation cancer immunotherapy: including AN8025 (a trifunctional fusion protein composed of αPD-L1 × CD86 variant × LAG3 variant, modulating T cells and antigen-presenting cells), and AN4005 (an oral small-molecule PD-L1 inhibitor).
For more information, please visit *.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Adlai Nortye Financing History (5 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

Adlai Nortye How Fast Is Hiring Growing? (26 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Down 59%
  • 2024: Down 58%
  • 2023: Up 194%
  • 2022: Down 79%
Adlai Nortye Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Adlai Nortye Campus Recruitment & Advanced Degree Talent Demand
Interns 1 Master's 14 Doctorate 4
Note: How fast is hiring at Hangzhou Adlai Nortye Biopharma Co., Ltd. growing? Adlai Nortye2026: 42 openings (up 367%), 2025: 9 openings (down 59%), 2024: 22 openings (down 58%), 2023: 53 openings (up 194%), 2022: 18 openings (down 79%), 2021: 87 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Adlai Nortye Master's Degree Job Demand Analysis

(More)
N/A
Growth Rate
Adlai Nortye Master's Hiring by Year: 2026
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Hangzhou Adlai Nortye Biopharma Co., Ltd. growing? Adlai NortyeMaster's recruitment over the years: 2026: 18 openings (up 367%), 2024: 3 openings (down 58%), 2023: 9 openings (up 194%), 2022: 2 openings (down 79%), 2021: 8 openings. Adlai Nortye master talent ranking in Hangzhou: #118, Adlai Nortye master salary mostly around 10-30K.

Adlai Nortye Doctoral Degree Job Demand Analysis

(More)
+50%
Growth Rate
2026 vs 2025
  • 2025: Down 73%
  • 2024: Down 25%
  • 2023: Up 122%
  • 2022: Up 800%
Adlai Nortye Doctoral Hiring by Year: 2026 — 2 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
No.82
Doctoral Demand Ranking in Hangzhou 򀀩
¥2-30K
Doctoral Salary 򀀩
How fast is doctoral hiring at Hangzhou Adlai Nortye Biopharma Co., Ltd. growing? Adlai NortyeDoctorate recruitment over the years: 2026: 6 openings (up 50%), 2025: 4 openings (down 73%), 2024: 15 openings (down 25%), 2023: 20 openings (up 122%), 2022: 9 openings (up 800%), 2021: 1 openings. Adlai Nortye doctorate talent ranking in Hangzhou: #82, Adlai Nortye doctorate salary mostly around 2-30K.

Adlai Nortye R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Hangzhou Adlai Nortye Biopharma Co., Ltd.? Based on an analysis of Adlai Nortye's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 42.9%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 35.7%, "Scientific Research": 28.6%, "Other (R&D and Technical)": 17.9%, "Electronics/Electrical/Communication Technology": 10.7%, "Computer/Network/Technology": 10.7%. For reference only.

Adlai Nortye — What Are the Salaries Like? (28 records)

Manage
Adlai Nortye Salary Overview
salary range: 2K - 50K, 64.3% of roles pay ¥10-30K
Note: salary statistics are based on 28 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Hangzhou Adlai Nortye Biopharma Co., Ltd.?Adlai Nortye64.3% of positions earn 10-30K, Undergraduate salary: ¥。Hangzhou salary ranking top 20,医疗卫生/美容保健类 average salary ¥26.9K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Adlai Nortye

(More)
Are salaries high at Hangzhou Adlai Nortye Biopharma Co., Ltd.? We provide: Product Manager, 临床, 科学家, Finance Specialist, MA, Process Engineer, pv, RA, Intern, Researcher, Project Management, BI Analyst, Customer Service, FA, Industrial Engineer, iOS Developer, Investor Relations, Statistician, Accountant, Cashier. Click to view detailed salary analysis by job.

Adlai Nortye honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 医疗卫生/美容保健类
    31% of total 31%
  • 生物/制药/化工/环保类
    26.2% of total 26.2%
  • 财务/审计/统计类
    26.2% of total 26.2%
  • 科研类
    23.8% of total 23.8%

Education

  • 硕士
    42.9% of total 42.9%
  • 本科
    38.1% of total 38.1%
  • 博士
    14.3% of total 14.3%
  • 大专
    2.4% of total 2.4%

Experience

  • 不限
    47.6% of total 47.6%
  • 3-5年
    23.8% of total 23.8%
  • 5-10年
    16.7% of total 16.7%
  • 1-3年
    11.9% of total 11.9%
View Detailed Analysis

What does Hangzhou Adlai Nortye Biopharma Co., Ltd. require? Who is Adlai Nortye hiring? Adlai Nortye recruitment: 医疗卫生/美容保健类占比最多占31%,其次是生物/制药/化工/环保类占26.2%. What education can get in at Adlai Nortye? 硕士占比最多占42.9%,其次是本科占38.1%. High education required at Adlai Nortye? 硕士占42.9%,博士占14.3%. Work experience required at Adlai Nortye? 不限占比最多占47.6%,其次是3-5年占23.8%. Where are the job locations at Adlai Nortye? 杭州占比最多占76.2%,其次是上海占11.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 20,000万(元)
Legal Representative: 路杨
Date Established:
Credit Code: 9133010176547745XB
Registered Address: 浙江省仓前街道向往街1008号8幢

Partners & Suppliers

百时美施贵宝提供Opdivo用于阿诺医药AN2025联合疗法的临床试验 Source
供应商 临床试验合作
默沙东提供Keytruda用于阿诺医药AN2025联合疗法的临床试验 Source
供应商 临床试验合作
阿诺医药获得诺华旗下buparlisib(AN2025)的全球独家许可 Source
供应商 技术授权/专利交叉许可
为阿诺医药提供抗体药物研发与生产服务 Source
供应商 CRO/CDMO

People who follow Adlai Nortye also follow

Adlai Nortye Competitors (Similar Companies)

“让原创药禧济天下”
生物科技/生物工程 生物制剂 药物研发 生物医药
“Synthetic biology technology developer”
分子诊断 基因测序 体外诊断/IVD 医学诊断
知识产权代理 律师事务所/法律服务 商标申请 商标事务所
新材料 聚乙烯/PE 化工/化学 塑料合金
精密机械零部件 机械零部件 生产 机械五金加工
服装/服饰 纺织 丝绸 化纤面料
工程设计 建筑幕墙 机电设备安装 门窗
环保/节能 品牌策划 环保科技/技术 艺术涂料
离心泵 多级离心泵 自动化 生产
安全设备 呼吸防护设备 生产 安全防护
开关电源 变电站 直流/DC电源 电力
造纸/造纸厂/纸业 打印纸 文化用纸 双面胶
模具 模具设计 模具开发 硅胶

Discover Great Companies, Discover Great Clients

杭州公司名录 杭州“Yuhang District”公司名录 杭州“制药/药业”公司名录 杭州“医药”公司名录 杭州“生命科学”公司名录 杭州“药物研发”公司名录 杭州“生物医药”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates